In this cohort study with prospective follow-up, we evaluated the safety and efficacy of the prescription of SGLT-2 inhibitors in T2DM patients at discharge from cardiology hospitalization. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.